Admetsys
- Company typePrivate
- Founded2010
- HeadquartersBoston, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
Admetsys firmographics
Firmographics- Name
- Admetsys
- Legal name
- Admetsys Corporation
- Website
- https://admetsys.com
- Company type
- Private
- Founded year
- 2010
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Admetsys industry classification
Industry- Product category
- Critical Care Medical Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Analytical Laboratory Instrument Manufacturing (334516), Surgical and Medical Instrument Manufacturing (339112)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Automated Insulin Delivery (AID) / Closed-Loop Systems (HLAHAHAF)
- akta.pro secondary industry
- Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators) (HLAHAHAJ)
Keywords
Where Admetsys is headquartered
LocationHeadquarters
- HQ city
- Boston
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Admetsys business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales
Revenue model
- Medical Device Sales: Admetsys generates revenue through the sale of its PrecisionOne™ clinical automation controller and Intravenous Laboratory™ continuous blood diagnostics system to hospitals and healthcare systems. The device is a capital equipment with consumable cartridge components. Revenue model appears to be hardware sales with potential recurring consumables revenue from replacement sensor cartridges. CE Mark approved for commercial use in EU/EEA; FDA clearance pending for US market.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels1 record
Admetsys product offering
Product offeringCore offering
Admetsys develops and sells an AI-powered clinical robotics system for blood analysis and metabolic control in critical care and surgical settings. The platform combines the PrecisionOne™ Clinical Automation Controller, which builds a real-time AI model of each patient's metabolism to autonomously regulate glucose via optimized insulin and dextrose infusion, with the Intravenous Laboratory™ (IVLab™), a cartridge-based extracorporeal biosensor providing up to 7 days of continuous zero-blood-loss measurement of glucose, lactate, hematocrit, and temperature (expandable to 20 analytes). The system is sold to hospitals and healthcare systems as capital medical-device hardware complemented by recurring consumable biosensor cartridges.
Product overview
Admetsys offers a unified clinical robotics system for blood analysis and metabolic control in critical care and surgery settings. The system consists of two integrated products: PrecisionOne™ (clinical automation controller) and Intravenous Laboratory™ (real-time continuous blood diagnostics). PrecisionOne captures biosensor data and constructs AI models of patient metabolism to autonomously regulate glucose, while Intravenous Laboratory provides continuous extracorporeal blood sensing for early sepsis detection. These products work together as a combined platform enabling high-precision automation that is adaptive to each individual patient and automatically implements clinician-set goals.
Differentiator
Problem solved
Functional benefit
Brands
- PrecisionOne™: Clinical automation controller that captures data from biosensors, constructs AI models of patient metabolism in real time, and autonomously regulates patient glucose through optimized insulin and dextrose therapy.
- Intravenous Laboratory™
- IVLab™
- Metabolic Autopilot™
Products and services
- PrecisionOne™ Clinical Automation Controller The PrecisionOne Clinical Automation Controller is an AI-driven medical device for adult critical care and surgical patients in hospital ICU and operating-room settings. It captures data from one or more biosensors, constructs an evolving computational (AI) model of each patient's metabolism in real time, and autonomously regulates patient glucose with zero clinician intervention by directly infusing continuously-optimized insulin and dextrose therapy. It has demonstrated 97% control between 80–125 mg/dL, 100% prevention of hypoglycemia under 70 mg/dL, and a 2.5-hour mean time to normoglycemia across 3 U.S. clinical trials.
- Intravenous Laboratory™ (IVLab™) Continuous Blood Diagnostics The Intravenous Laboratory (IVLab) is a cartridge-based extracorporeal whole-blood biosensing system for adult critical care and surgical patients. It provides zero-blood-loss continuous measurement across 4 analytes (blood glucose, lactate, temperature, hematocrit) expandable to 20 analytes for up to 7 days of continuous biosensing. Lactate measurement enables early detection and mitigation of sepsis, and the IVLab biosensor data informs PrecisionOne's glucose regulation function. It is sold to hospitals as a recurring consumable cartridge platform paired with the PrecisionOne controller.
Quantifiable outcome
- 34% reduction in mortality with glucose control
- +9 more outcomes
Companies that use Admetsys
Customer profileSegments1 record
Ideal customer profiles1 record
Admetsys technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability1 record
Feature4 records
Admetsys partnerships and signals
Strategic signalScale indicators5 records
Recent moves6 records
Expansion highlights4 records
Admetsys competitors and assessment
Company assessmentDirect peers
- Glytec: Glytec's eGlycemic Management System is software for hospital insulin dosing, the closest software analog to Admetsys' autonomous glycemic control. Both target ICU/hospital glucose management with dose-decision automation.
- Monarch Medical Technologies: Monarch's EndoTool is a hospital insulin dosing decision-support platform used in critical care. It directly overlaps Admetsys' PrecisionOne use case of automated glycemic management in the ICU.
- OptiScan Biomedical: OptiScan develops continuous glucose monitoring systems for the ICU, comparable to Admetsys' IVLab component. Both provide real-time hospital glucose biosensing intended for critical care glycemic management.
- Nova Biomedical: Nova Biomedical manufactures blood gas and hospital glucose analyzers including critical care analyzers. Their StatStrip and hospital blood chemistry platforms overlap with IVLab's continuous ICU biosensing value proposition.
Broad incumbents
- Medtronic: Medtronic has a major diabetes franchise (MiniMed AID systems, Guardian CGM) and a hospital infusion pump portfolio. While focused on ambulatory diabetes, the company has the resources and ICU channels to enter autonomous critical care glycemic control.
- Dexcom: Dexcom is the leading continuous glucose monitor manufacturer and is expanding into hospital/ICU use cases (Dexcom hospital program). Its CGM technology is comparable to the IVLab continuous biosensing function.
- Abbott Diabetes Care: Abbott's FreeStyle Libre is the dominant CGM globally and Abbott has hospital-facing diagnostics. As a large diversified medtech incumbent, it is positioned to enter or enable autonomous critical care glycemic management.
- B. Braun: B. Braun is a global leader in hospital infusion systems (Infusomat, Perfusor) and has its own diabetes care unit. Its installed infusion pump base and ICU relationships make it a potential competitor or partner for Admetsys' closed-loop insulin/dextrose therapy.
Emerging players
- Tandem Diabetes Care: Tandem's t:slim X2 with Control-IQ is a leading automated insulin delivery system for ambulatory diabetes. While focused outside the ICU, its closed-loop AID architecture is conceptually adjacent to Admetsys' autonomous dosing model.
- Insulet: Insulet's Omnipod 5 is an automated insulin delivery system for ambulatory diabetes. Its AID technology platform is adjacent to Admetsys' autonomous insulin/dextrose infusion approach, though the clinical setting differs.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Admetsys social profiles
Digital presenceAdmetsys compliance and trust
Trust signalCompliance2 records
Admetsys financial estimates
Financial estimateRevenue estimate
Valuation estimate
Admetsys leadership team
Management profileNumber of profiles
Profiles3 records
Admetsys funding detail
Funding detailFunding overview
Funding rounds4 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Admetsys M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Admetsys
What does Admetsys do?
Admetsys develops and sells an AI-powered clinical robotics system for blood analysis and metabolic control in critical care and surgical settings. The platform combines the PrecisionOne™ Clinical Automation Controller, which builds a real-time AI model of each patient's metabolism to autonomously regulate glucose via optimized insulin and dextrose infusion, with the Intravenous Laboratory™ (IVLab™), a cartridge-based extracorporeal biosensor providing up to 7 days of continuous zero-blood-loss measurement of glucose, lactate, hematocrit, and temperature (expandable to 20 analytes). The system is sold to hospitals and healthcare systems as capital medical-device hardware complemented by recurring consumable biosensor cartridges.
Is Admetsys a public or private company?
Admetsys is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Admetsys founded?
Admetsys was founded in 2010. It employs 1 to 10 people.
Where is Admetsys based?
Admetsys is headquartered in Boston, United States, in the North America region.
How does Admetsys make money?
One revenue line is on record: medical Device Sales.
Who are Admetsys's main competitors?
Direct peers on record are Glytec, Monarch Medical Technologies, OptiScan Biomedical and Nova Biomedical. Broad incumbents are Medtronic, Dexcom, Abbott Diabetes Care and B. Braun. Emerging players are Tandem Diabetes Care and Insulet.
Does Admetsys have an API?
No public API is recorded for Admetsys.
What industry is Admetsys in?
Admetsys's product category is Critical Care Medical Devices. Its primary akta.pro industry code is HLAHAHAF, Automated Insulin Delivery (AID) / Closed-Loop Systems, with a secondary code of HLAHAHAJ, Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators). Its NAICS code is 334510 and its SIC code is 3845.